Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

Open access
Konteatis, Zenon, Artin, Erin, Nicolay, Brandon, Straley, Kimberly, Padyana, Anil K., Jin, Lei, Chen, Yue, Narayaraswamy, Rohini, Tong, Shuilong, Wang, Feng, Zhou, Ding, Cui, Dawei, Cai, Zhenwei, Luo, Zhiyong, Fang, Cheng, Tang, Huachun, Lv, Xiaobing, Nagaraja, Raj, Yang, Hua, Su, Shin-San M., Sui, Zhihua, Dang, Lenny, Yen, Katharine, Popovici-Muller, Janeta, Codega, Paolo, Campos, Carl, Mellinghoff, Ingo K., Biller, Scott A.·2020·ACS Medicinal Chemistry Letters

Abstract

Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite d-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation. Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. X-ray cocrystal structures allowed us to characterize the compound binding site, leading to an understanding of the dual mutant inhibition. Furthermore, vorasidenib penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopic glioma mouse model. Vorasidenib represents a novel dual mIDH1/2 inhibitor and is currently in clinical development for the treatment of low-grade mIDH glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsmedchemlett.9b00509

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 199

Metadata

Authors
Konteatis, Z., Artin, E., Nicolay, B., Straley, K., Padyana, A. K., Jin, L., Chen, Y., Narayaraswamy, R., Tong, S., Wang, F., Zhou, D., Cui, D., Cai, Z., Luo, Z., Fang, C., Tang, H., Lv, X., Nagaraja, R., Yang, H., Su, S.-S. M., Sui, Z., Dang, L., Yen, K., Popovici-Muller, J., Codega, P., Campos, C., Mellinghoff, I. K., & Biller, S. A.
Venue
ACS Medicinal Chemistry Letters
Published
2020-01-22
Volume
11
Issue
2
Pages
101-107
ISSN
1948-5875 (ISSN-L)
OpenAlex
W3002439510
Cited by
199
References
7
FWCI
10.49
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. https://app.cochat.ai/papers/10.1021/acsmedchemlett.9b00509
The paper
Konteatis, Z., Artin, E., Nicolay, B., Straley, K., Padyana, A. K., Jin, L., Chen, Y., Narayaraswamy, R., Tong, S., Wang, F., Zhou, D., Cui, D., Cai, Z., Luo, Z., Fang, C., Tang, H., Lv, X., Nagaraja, R., Yang, H., . . . Biller, S. A. (2020). Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.9b00509

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.